Total revenues were $144.8 million, a 13 percent increase on a constant currency basis, and beating the average analysts' estimate of $140.2 million.
Evidence is mounting supporting the use of self-collected specimens for HPV and other infectious disease testing in both the developing and developed world.
The partnership is the second this year aimed at widening distribution of the GeneXpert to moderately complex labs in the US.
The upgraded test includes new gene targets for methicillin resistance, and provides room-temperature storage and validation on multiple swab types.
The test is the 20th US-IVD molecular diagnostic on the GeneXpert menu — Cepheid also recently announced that it has now placed its 10,000 systems globally.
The firm attributed the growth to record reagent revenues and GeneXpert system placements.
Executives from several life science research tool and diagnostic firms provided conference attendees with updates on their businesses.
Cepheid will create Xpert cartridge tests to detect S. aureus and P. aeuginosa, to be used in clinical trials for biologics intended to prevent pneumonia.
The firm reported preliminary financial results in line with previous guidance and the average Wall Street estimate.
The firm signed a memorandum of understanding with the agency and is expected to detail the terms of the cooperation in a subsequent collaborative agreement.
Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.
St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.
St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.
In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.